Known targets — ChEMBL curated mechanism
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
The experimentally established mechanism targets of Phosphoric Acid. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LAP3 | P28838 | 4/20 | 0.46 |
| ▸ | GABBR2 | O75899 | 4/20 | 0.44 |
| ▸ | GABBR1 | Q9UBS5 | 4/20 | 0.44 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.43 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.42 |
| ▸ | GABRR1 | P24046 | 1/20 | 0.42 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.42 |
| ▸ | TSHR | P16473 | 1/20 | 0.42 |
| ▸ | THPO | P40225 | 1/20 | 0.42 |
| ▸ | METAP1 | P53582 | 1/20 | 0.41 |
| ▸ | ANPEP | P15144 | 3/20 | 0.40 |
| ▸ | ERAP1 | Q9NZ08 | 1/20 | 0.40 |
| ▸ | MEN1 | O00255 | 1/20 | 0.40 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Phosphoric Acid SCHEMBL6510662 | 0.87 | FDPS (0.48) | LAP3GABBR2GABBR1ALDH1A1GABRR1 | |
| Phosphoric Acid SCHEMBL17700976 | 0.87 | FDPS (0.48) | LAP3GABBR2GABBR1ALDH1A1GABRR1 | |
| Phosphoric Acid SCHEMBL1204384 | 0.87 | FDPS (0.48) | LAP3GABBR2GABBR1ALDH1A1GABRR1 | |
| Phosphoric Acid SCHEMBL297335 | 0.87 | — | — | |
| Phosphoric Acid SCHEMBL11408484 | 0.87 | FDPS (0.48) | LAP3GABBR2GABBR1ALDH1A1GABRR1 | |
| Phosphoric Acid SCHEMBL18039006 | 0.83 | FDPS (0.46) | LAP3GABBR2GABBR1ALDH1A1GABRR1 | |
| Phosphoric Acid SCHEMBL3401297 | 0.83 | — | — | |
| Phosphoric Acid SCHEMBL1301741 | 0.83 | — | — | |
| Phosphoric Acid SCHEMBL31689367 | 0.83 | FDPS (0.46) | LAP3GABBR2GABBR1ALDH1A1GABRR1 | |
| Ethylamine SCHEMBL19327142 | 0.79 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3822259-B1 | METHOD FOR SYNTHESIZING VALSARTAN | ZHEJIANG HUAHAI PHARM CO LTD (CN) | 2025-08-27 | — | — | EP | claimed |
| US-11434210-B2 | Method for synthesizing valsartan | ZHEJIANG HUAHAI PHARMACEUTICAL CO., LTD (CN) | 2022-09-06 | — | — | US | claimed |
| EP-3822259-A1 | METHOD FOR SYNTHESIZING VALSARTAN | Zhejiang Huahai Pharmaceutical Co., Ltd. (CN) | 2021-05-19 | — | — | EP | claimed |
| EP-3822259-B1 | METHOD FOR SYNTHESIZING VALSARTAN | ZHEJIANG HUAHAI PHARM CO LTD (CN) | 2025-08-27 | — | — | EP | disclosed |
| US-11434210-B2 | Method for synthesizing valsartan | ZHEJIANG HUAHAI PHARMACEUTICAL CO., LTD (CN) | 2022-09-06 | — | — | US | disclosed |
| EP-3822259-A1 | METHOD FOR SYNTHESIZING VALSARTAN | Zhejiang Huahai Pharmaceutical Co., Ltd. (CN) | 2021-05-19 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11434210-B2 | Method for synthesizing valsartan | REN, ACE, AGT | LAP3 286/4885GABBR2 2546/4885GABBR1 2781/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.